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Summary 
Vaccinia virus (VV) and other orthopoxviruses express 
a soluble type I interferon (IFN) receptor that for VV 
strain Western Reserve is encoded by gene B18R. The 
80-85 kDa glycoprotein is related to the interleukin-1 
receptors and is a member of the immunoglobulin su- 
perfamily, unlike other type I IFN receptors, which be- 
long to the class II cytokine receptor family. The recep- 
tor has high affinity (KD, 174 PM) for human IFNa and, 
unlike other type I IFN receptors, has broad species 
specificity, binding to human, rabbit, bovine, rat, and 
mouse type I IFNs. This may have aided VV replication 
in multiple host species during evolution. A VV B18R 
deletion mutant is attenuated in a murine intranasal 
model. This type I IFN receptor represents the fourth 
VV protein that interferes with IFN and the fourth solu- 
ble cytokine receptor expressed by poxviruses. 
Introduction 
lnterferons (IFNs) are a heterogeneous family of cytokines 
that were initially defined by their ability to induce resis- 
tance to viral infection (Isaacs and Lindermann, 1957). 
The various IFNa subtypes and IFNP (type I IFNs) share 
sequence similarity and bind common, species-specific 
receptors on host cells (for reviews, see Peska and Langer, 
1987; Callard and Gearing, 1994). IFNy (type II IFN) binds 
to a different receptor (Aguet et al., 1988). In addition to 
their antiviral effects, IFNs exhibit other biological proper- 
ties, including regulation of cellular differentiation, prolifer- 
ation, and immunomodulation. 
Two human type I IFN receptors have been character- 
ized. By use of a gene transfer approach, a 95-110 kDa 
type I membraneglycoprotein was identified that mediates 
responses to IFNa8 but not to other human IFNa subtypes 
or to IFNp (Uze et al., 1990). More recently, a second type 
I IFN receptor was cloned after the identification, purifica- 
tion, and sequence analysis of a 40 kDa soluble form of 
the receptor. The membrane-associated form is a 51 kDa 
glycoprotein that is disulphide-bonded into a 102 kDa ho- 
modimer that binds to most IFNa subtypes and to lFNf3 
(Novick et al., 1994). A mouse IFNa receptor related to 
the human 95-110 kDa receptor has also been cloned 
(Uze et al., 1992) that mediates the activities of all the 
mouse type I IFN subspecies. The type I IFN receptors 
possess two or four fibronectin type Ill domains and belong 
to the class II cytokine receptor family (CRFP) that includes 
the receptors for IFNy and interleukin (IL)-10 and the 
CRF2-4 gene product. These exhibit 200/o-30% amino 
acid identity and share common motifs, including two cys- 
teine pairs and conserved proline, tryptophan, and tyro- 
sine residues (Callard and Gearing, 1994). 
Targeted deletion of the mouse type I IFN receptor has 
revealed that the type I IFN system is essential for host 
defense against some viruses. Mutant mice became 1 06- 
fold to lo’-fold more sensitive to vesicular stomatitis virus 
and Semliki Forest virus than normal mice (Muller et al., 
1994). In contrast, inactivation of the type II IFN system 
had no effect on infection with these viruses. However, 
functional type I and type II IFN systems are required for 
defense against lymphocytic choriomeningitis virus and 
vaccinia virus (VV) (Muller et al., 1994). 
VV is the prototypic member of the poxvirus family of 
cytoplasmic DNA viruses (Moss, 1990) and is the live vac- 
cine used to eradicate smallpox (Fenner et al., 1988). The 
191 kbp viral genome has approximately 200 genes 
(Goebel et al., 1990; Johnson et al., 1993) and isorganized 
with essential genes, such as those encoding enzymes 
required for replication and transcription, clustered toward 
the genome center, whereas nonessential genes influenc- 
ing host range and virulence map toward the termini. Sev- 
eral of these latter genes encode proteins involved in the 
evasion of the host immune response to infection (Smith, 
1993). 
IFN is important for protection against poxvirus infec- 
tions. Mice with a targeted disruption of the type I or type 
II IFN system are more susceptible to infection by VV, 
despite a normal cytotoxic T cell response (Dalton et al., 
1993; Huang et al., 1993; Muller et al., 1994). Treatment 
of mousepox virus-infected mice with neutralizing anti- 
bodies to either type I or type II IFN resulted in defective 
clearance of virus (Karupiah et al., 1993a), whereas treat- 
ment of mice with IFN prior to infection with VV abrogates 
the infection (Rodriguez et al., 1991). Furthermore, 
athymic nude mice infected with a recombinant VV ex- 
pressing IFNy recovered from infection, whereas mice in- 
fected with a wild-type W died (Kohonen-Corish et al., 
1990). Lastly, the inhibition of nitricoxidesynthasein mice, 
which mediates the antiviral activity of IFNT, converts a 
resolving infection into fulminant mousepox (Karupiah et 
al., 1993b). 
Poxviruses have several strategies to counteract the ac- 
tion of IFN. The VV E3L protein competitively binds double- 
stranded RNA (dsRNA) and prevents the activation of the 
IFN-induced and dsRNA-activated protein kinase PKR 
(Chang et al., 1992). In addition, the VV K3L protein has 
sequence similarity with eukaryotic initiation factor 2a 
(elF2a) that is phosphor-ylated and inactivated by PKR 
(Beattie et al., 1991). The K3L protein competitively binds 
PKR and hence blocks the phosphorylation and inactiva- 
tion of host elFPa. However, these mechanisms can only 
block the IFN response within infected cells, and to sup- 
press cytokine responses more broadly, poxviruses use 
other strategies, such as the expression of soluble cyto- 
Cdl 
552 
A 
80 
100 
B 
kine receptors. Myxoma virus, a leporipoxvirus, expresses 
an IFNy receptor that binds and inhibits rabbit IFNy (Upton 
et al., 1992), and the otthopoxviruses vaccinia, cowpox, 
and camelpox encode a soluble IFNy receptor of broad 
species specificity (Alcami and Smith, submitted). Myx- 
oma virus expresses a tumor necrosis factor (TNF) recep- 
tor that contributes to virus virulence (Upton et al., 1991), 
and Shope fibroma virus (Smith et al., 1991) and cowpox 
virus (Hu et al., 1994) also encode a soluble TNF receptor. 
VV and cowpox virus secrete an IL-l p receptor (a member 
of the immunoglobulin superfamily [IgSF]) that modulates 
the host response to infection (Alcami and Smith, 1992; 
Spriggs et al., 1992). VV gene B18R also encodes an IgSF 
member that is distantly related to B15R and the IL-1 and 
IL-8 receptors (McMahan et al., 1991; Smith and Chan, 
1991) but fails to bind either cytokine (Alcami and Smith, 
1992; Spriggs et al., 1992; Morikawa and Ueda, 1993). 
Here, we demonstrate that B18R encodes a soluble type 
I IFN receptor with high affinity for human type I IFN. This 
receptor contributes to VV virulence, has novel broad spe- 
cies specificity, and belongs to a protein superfamily differ- 
ent from those of other type I IFN receptors. 
Results 
Vaccinia Virus Encodes a Soluble IFNa Inhibitor 
To determine whether VV encoded a soluble inhibitor of 
type I IFN, virus-free supernatants from mock-infected or 
VV strain Western Reserve (WR)-infected ceils were incu- 
bated with increasing concentrations of human natural 
IFNa on HeLa cells, and these cells were subsequently 
challenged with coca1 virus, a rhabdovirus similar to vesic- 
ular stomatitis virus. Figure 1A shows that cells infected 
with coca1 virus were lysed, but IFNa at 220 U/ml protected 
cells from this cytopathic effect (CPE). However, cultures 
Figure 1. Supernatants from VV-Infected 
Cells Contain an Inhibitor of IFNa Widely Dis- 
tributed in Orthopoxviruses 
(A) Supernatants from W-infected cells con- 
tain an inhibitor of IFNa. Monolayers of human 
HeLa cells were incubated with or without hu- 
man natural IFNa at the indicated concentra- 
tions in the presence of either media alone (Me- 
dia), or supernatants from lo3 TK-1436 cells 
either mock infected (Mock)or infected with VV 
strain WR (WR). After an 18 hr incubation at 
37“C, the cells were challenged with 1000 pfu 
of coca1 virus and 48 hr later stained with 0.1% 
crystal violet in 15% ethanol. 
(B) Distribution of IFNa inhibitor in orthopoxvi- 
ruses. Supernatants from lo3 TK-143B cells 
infected with various W strains or other ortho- 
poxviruses were tested for their ability to inhibit 
the biological activity of 5 U of human natural 
IFNa. After 18 hr. the cells were challenged 
with 100 pfu of coca1 virus and incubated for 
a further 48 hr in media containing 1.5% (w/v) 
carboxymethylcellulose before staining with 
0.1% crystal violet in 15% ethanol and count- 
ing plaque numbers. The percentage inhibition 
of IFNa activity was calculated as described in 
Experimental Procedures. 
incubated with supernatants from WR-infected cells, but 
not mock-infected cells, developed CPE even in the pres- 
ence of 40 U/ml IFNa. This CPE was not due to a VV 
infection, because no CPE occurred without coca1 virus. 
Thus, WR supernatants contained an inhibitor of the IFNa 
subtypes present in natural human IFNa. 
The IFNa Inhibitor Is Widely Distributed 
in Otthopoxviruses 
To investigate how widely the IFNa inhibitor was distrib- 
uted in orthopoxviruses, cells were infected with 14 VV 
strains (including rabbitpox and buffalopox), two strains 
of cowpox virus (Brighton red and elephantpox) and cam- 
elpox virus, and the cell supernatants were tested for inhi- 
bition of IFNa activity (Figure 1 B). Inhibitory activity was 
found in all VV strains except Lister, but the activity was 
low in strain Wyeth. The lack of activity with strain Lister 
and the low level of activity with strain Wyeth were not due 
to a poor infection, as supernatants from Lister-, Wyeth-, or 
WR-infected cells inhibited IFNy to a similar extent (data 
not shown). Cowpox, elephantpox, and camelpox also ex- 
pressed an inhibitor of type I IFN, although this was at 
very low levels with camelpox. 
Mapping of the Soluble IFNa Inhibitor 
To map the VV gene encoding the soluble IFNa inhibitor, 
we used viruses v6/2 (Moss et al., 1981), vGS100, and 
vSSK2 (N. W. Blake, K. M. Law, S. Kettle, and G. L. S., 
unpublished data), which have large deletions in the lefi 
or right ends of the genome (Figure 2A). These regions 
were selected for study because other VV genes that ex- 
press soluble modulators of the immune response to infec- 
tion are encoded here (Smith, 1993). Supernatants from 
cells infected with these viruses were tested for their ability 
to inhibit the bioactivityof human natural IFNa or recombi- 
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Figure 2. Mapping of the VV WR Gene Encoding the Soluble IFNa 
inhibitor to B18R 
(A) Hindlll restriction endonuclease map of the WR genome. The re- 
gions deleted in mutant viruses v6/2, vGS100, and vSSK2 are indi- 
cated by broken horizontal lines. The ITRs are shown boxed on the 
WR genome. 
(B) Inhibition of IFNa and IFNy activity by W WR and mutant viruses. 
Monolayers of HeLa cells were incubated with supernatants from 103 
cells infected with viruses WR, ~612, vGS100, or vSSK2 and either 5 
U of human natural IFNa or recombinant IFNy for 18 hr at 37%. The 
cells were then infected with approximately 100 pfu of coca1 virus and 
incubated for a further 48 hr at 37% in media containing 1.5% (w/v) 
carboxymethylcellulose. The percentage inhibition of the IFN activity 
was assessed as described in Experimental Procedures. 
(C) Identification of B18R as the type I IFN inhibitor. Monolayers of 
HeLa cells were incubated with supernatants from 101 TK-143B cells 
infected with either W WR, vAB15R, or vAB18R and either human 
natural IFNa (hnlFNa), or human recombinant IFNa2 (hrlFNaP), lFN8 
(hrlFNf3), or IFNy (hrlFNy). The IFNs were also incubated with superna- 
tants from 103 Sf cells infected with recombinant baculovirus express- 
ing B15R (AcB15R), B8R (AcBBR), or B18R (AcB18R). Experimental 
details were as described in (B). Bars indicate the mean f standard 
error of the mean (SEM); n = 4. 
nant IFNY. Figure 2B shows that supernatants from cells 
infected with WR, v6/2 (a strain of VV WR with a 9 kb 
deletion near the left inverted terminal repeat [ITRJ), or 
vGSlO0 (a strain of VV WR lacking gene B22R and all 
genes rightward up to the gene encoding a 7.5 kDa poly- 
peptide within the right ITR) inhibited the biological activity 
of IFNa. However, supernatants from vSSK2 (a strain of 
VV WR lacking genes B13R to 821 R in addition to those 
missing in vGS100) did not inhibit the bioactivityof IFNa. In 
contrast, all four virusesexpressed asoluble IFNy receptor 
encoded by gene B8R (Alcamf and Smith, submitted). 
Thus, the gene encoding the IFNa inhibitor mapped be- 
tween B13R and B21R. 
This region contains only two genes, B15R and B18R, 
predicted to encode secreted proteins (Smith and Chan, 
1991; Smith et al., 1991) and B15R encodes a soluble 
IL-16 receptor (Alcami and Smith, 1992; Spriggs et al., 
1992). To determine whether B15R or B18R encoded the 
IFNa inhibitor, supernatants from cells infected with vi- 
ruses lacking either gene, vAB15R or vABl8R (Alcami 
and Smith, 1992) were tested for inhibition of IFN activity 
(Figure 2C). Supernatants from WR and vAB15R inhibited 
both type I (IFNa and IFN8) and type II IFN (IFNy) activity, 
but those from vAB18R-infected cells inhibited only IFNy 
activity. This result was confirmed by using supernatants 
from Spodoptera frugiperda (S9 insect cells infected with 
recombinant baculoviruses expressing either B15R or 
B18R (Alcami and Smith, 1992) or B8R, a gene encoding 
a soluble IFNy receptor (Alcami and Smith, submitted). 
Supernatants containing B18R (AcB18R) inhibited type I 
IFN, and those containing B8R (AcB8R) inhibited type II 
IFN, whereas B15Rcontaining supernatants(AcB15R) in- 
hibited neither type of IFN. Gene B18R, therefore, en- 
codes a type I IFN inhibitor. 
The Bl8R Protein Blocks the Binding of IFNa 
to Its Cell Surface Receptor 
The biological inhibition of type I IFN mediated by B18R 
might occur by degradation of IFNa or by blocking either 
the binding of IFN to cell receptors or some step of the 
IFN-responsive signaling pathway. The possible degrada- 
tion of IFN was eliminated by the observed stability of 
‘zl-IFNa2 in the presence of the B18R protein (data not 
shown). Next, the potential of B18R to block IFNa2 binding 
to its cell receptor was investigated. Figure 3A shows that 
human ‘251-IFNa2 specifically bound to atype I IFN recep- 
tor on U937 cells, and this binding was inhibited by cold 
IFNa and IFNf3, but not by IFNY. Similarly, supernatants 
from mammalian cells infected with WR and vAB15R, but 
not from uninfected or vAB18R-infected cells, and super- 
natants from insect cells infected with recombinant bacu- 
lovirus AcB18R, but not AcB6R or AcB15R, inhibited the 
binding of the IFN to U937 cells. The B18R protein, there- 
fore, blocks binding of type I IFN to its cell receptor. 
The B18R Protein Binds Type I IFN 
The above result suggested that the B18R protein might 
bind to type I IFN. This was tested in soluble binding 
assays with human ‘%I-IFNa2 (Figure 38). Supernatants 
from WR-infected cells bound to IFNa2, and the specificity 
of this binding was shown by its inhibition with cold human 
type I IFNs but not with type II IFN. B18R was confirmed 
as the IFN-binding protein by the binding of ‘251-IFNa2 to 
supernatants from cells infected with WR and vAB15R but 
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Figure 3. B18R Blocks the Binding of IFNa2 to Its Cell Surface Recep- 
tor and Is a Soluble Receptor for Type I IFN 
(A) Ten nM of ‘251-IFNa2 and 1 OB U937cells were incubated with super- 
natants from lo5 WR-infected or 5 x IO4 baculovirus-infected cells or 
with a lOO-fold excess of cold IFNa, IFN6, or IFN+r. After 2 hr at 4OC 
with constant gentle agitation, the cells were washed twice and bound 
and free 1*51-IFNa2 separated by centrifugation through phthalate 
oil. Experiments were performed in duplicate tubes. Bars indicate 
mean f SEM; n = 3. 
(6) Supernatants from lo5 TK-143B cells infected with W WR, 
vABi5R, orvAB16Rorfrom 5 x 104Sfcellsinfected with recombinant 
baculoviruses AcB15R or AcB16R were incubated at 20% for 90 min 
with 50 nM human ‘251-IFNa2 with or without a IOO-fold excess of cold 
human IFNa, IFN5, or IFNT. Receptor-bound ‘=I-IFN was separated 
from free Y-IFN by filtration through GF/C glass fiber filters after 
addition of PEG. Experiments were performed in duplicate tubes and 
results expressed as specific binding after subtraction of nonspecific 
binding. Bars indicate mean f SEM; n 3 3. 
not vAB18R. In addition, supernatants from cells infected 
with recombinant baculovirus AcB18R, but not Ac68R or 
AcB15R specifically bound the 1251-IFNa2. These results 
demonstrated that B18R was a novel soluble receptor for 
type I IFN. 
Characterization of the B18R Gene Product 
Previously, the B18R gene was shown to be transcribed 
and translated early during infection (Ueda et al., 1990; 
AlcamiandSmith, 1992). This wasconfirmed byobserving 
that supernatants from cells infected with VV WR in the 
B 123 4 5 6 
Figure 4. Ligand Blotting of BIER with ‘=I-IFNa2 
(A) Supernatants from lo5 WR-infected cells (lanes 1, 3,4, and 5) and 
vAB16R-infected cells (lane 2) were resolved by SDS-PAGE under 
nonreducing conditions and transferred onto nitrocellulose. After 
blocking, the filters were probed with 10 nglml ‘251-IFNa2 alone (lanes 
1 and 2)orwith 106foldexcessof cold competitor human recombinant 
IFNu2 (lane 3), lFNf3 (lane 4) or IFNy (lane 5). 
(B) Supernatants from 1O’Sf cells infected with recombinant baculovi- 
rus expressing B16R (lanes 1, 4, 5, and 6) B6R (lane 2), or B15R 
(lane 3) were treated as in (A). Filters were probed with 10 rig/ml Y- 
IFNa2 alone (lanes 1,2, and 3) or with 1 00-fold excess of cold human 
recombinant IFNa2 (lane 4), lFN5 (lane 5) or IFNy (lane 6). Protein 
markers are in kilodaltons. 
presence of cytosine arabinoside (an inhibitor of DNA syn- 
thesis and VV late gene expression) also contained an 
IFNa inhibitory activity (data not shown). The size of the 
B18R protein has been reported as either 40 kDa when 
translated in vitro (Ueda et al., 1990) or 80-65 kDa when 
secreted from VV-infected cells (Alcami and Smith, 1992). 
This was further analyzed by ligand blotting (Figure 4). 
Supernatants from either W-or recombinant baculovirus- 
infected cells were resolved by sodium dodecyl sulfate- 
polyacrylamide gel electrophoresis (SDS-PAGE) under 
nonreducing conditions, blotted onto nitrocellulose, and 
probed with ‘251-IFNa2 with or without cold competitors. 
The supernatant from cells infected with WR but not 
vABl8R contained a protein that bound ‘251-IFNa2 and 
migrated at approximately 59 kDa (Figure 4A). An identi- 
cally sized protein was detected after infection with all 
orthopoxviruses tested except W strains Lister, Wyeth, 
and camelpox (data not shown). Recombinant baculovi- 
rus-derived B18R, but not B8R or B15R, also bound to 
‘251-IFNa2; however, the molecule migrated at 38 kDa(Fig- 
ure 4B), consistent with the smaller size of the B18R pro- 
tein (48 kDa) expressed from insect cells (Alcami and 
Smith, 1992; Morikawa and Ueda, 1993). The binding of 
1251-IFNa2 to B18R derived from either W or AcBl8R was 
specific, as the binding was competed with a lOO-fold ex- 
cess of cold type I but not type II IFN. 
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Supernatants from 10STKml 438 cells infected 
with WR (A), 5 x 103 Sf cells infected with 
AcB16R (B), or 10eTK-143Bcells infected with 
W strain Wyeth (C) were incubated in 0.2 ml 
with different concentrations of ‘2SI-IFNa2 and 
specific bound radiolabeled ligand determined 
by the PEG precipitation technique. Data were 
converted to the Scatchard coordinate system. 
Figure 5. Scatchard Analysis of Human ‘St- 
IFNa2 Binding to the W lFNalf3 Receptor 
sound [PM, sound ,pbs, 
Interferon Binding Characteristics 
of the B18R Protein 
The binding affinity of B18R for human 1*51-IFNa2 was 
assessed by Scatchard analyses (Figure 5). Supernatants 
from WR-, Wyeth-, and AcB18Rinfected cells each 
showed saturation binding (data not shown). Scatchard 
analysis of the WR supernatant revealed single site-bind- 
ing kinetics with a KD of 174 f 15 pM (Figure 5A) and 
1.13 x 10“ f 0.05 x lo4 binding sites secreted during 
24 hr per infected cell. This affinity is similar to that re- 
ported for human IFNaA and the type I IFN receptor on 
human U937 cells (KD, 300 PM) (Langer and Peska, 1986) 
and to our data (not shown) indicating 3.6 x lo3 high 
affinity sites with a KD of 440 pM on U937 cells. The B18R 
protein secreted from insect cells (Figure 58) had a 3-fold 
lower affinity (KD, 527 f 40 PM) than the VV W&derived 
protein, but the number of binding sites produced during 
a 72 hr infection was much greater (2.27 x lo6 f 0.11 
x 106), reflecting the high level of expression in the bacu- 
lovirus system. Because W strain Wyeth produced only 
low IFNa-inhibitory activity (Figure lB), we assessed 
whether this was due to low receptor expression or low 
affinity for the ligand. Scatchard analysis (Figure 5C) re- 
vealed a similar number of binding sites per cell (1.50 x 
lo4 f 0.06 x 103 compared with the number for WR, 
but with a KD of only 13.5 f 0.83 nM, 76-fold lower than 
the WR B18R protein. 
Species Specificity of the VV Type I IFN Receptor 
The relative binding affinities of B16R for type I IFN from 
different species were compared by competition binding 
of unlabeled IFNs with human ‘251-IFNa2. Equilibrium dis- 
sociation constants were calculated from the ECso values 
using the Cheng-Prusoff relationship (Cheng and Prusoff, 
1973). These calculations were based on a KD of 174 pM for 
the binding of human 1z51-IFNa2 to the WR B18R protein 
(Figure 5A) and could only be performed where the com- 
petitor contained only one subtype of IFN. The competitive 
binding curves (Figure 6A) revealed that type I IFN from 
different species bound to the WR B18R protein with vary- 
ing affinities. Human and rabbit type I IFN bound to B16R 
with indistinguishable high affinity, and bovine and rat 
IFNa bound with reduced affinity, with an estimated KD in 
the case of bovine IFNal of 1 nM, whereas mouse type 
I IFNs bound with low affinity, with an estimated KD of 27 
nM for mouse IFNf3. 
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Figure 6. Species Specificity of B16R Binding and Inhibition of Type 
I IFN 
(A) Cross-competition of human ‘=I-IFNa2 binding to the supernatant 
from lo5 WR-infected cells. ‘?-IFNa2 (10 nM) was incubated with 
soluble W WR IFN type I receptor together with increasing concentra- 
tions of cold human recombinant IFNa2 (closed squares), human re- 
combinant lFN6 (open squares), bovine recombinant IFNal (open cir- 
cles), natural rat type I IFN (shaded triangles), mouse natural IFNa 
(closed triangles), mouse natural IFNp (open triangles), and natural 
rabbit type I IFN (shaded circles) for 2 hr at 20%. Ligand-receptor 
complexes were separated from free ligand by precipitation with PEG. 
The concentrations of the cold IFNs were calculated from their known 
biological activities per microgram of protein and are expressed as 
the concentrations of active IFN. 
(B) Various concentrations of supernatant from WR-infected cells were 
incubated with 5 U of either human natural IFNa (closed squares), 
mouse natural IFNa (closed triangles), bovine recombinant IFNal 
(open circles), or natural rabbit (shaded circles) or natural rat type I 
IFN (shaded triangles) with cells of the appropriate species (human, 
HeLa cells; mouse, L929 cells; bovine, MDBK cells; rabbit, RK13 cells; 
and rat, NRK cells). After 16 hr, 100 pfu of coca1 virus were added 
and the culture incubated for a further 46 hr, before staining with crystal 
violet and counting plaques. The percentage inhibition of the IFN activ- 
ity was calculated as described in the Experimental Procedures. 
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Table 1. Effect of B18R Deletion on Vaccinia Virus Virulence 
in Mice 
Dose (pfu) WR VA810R vB18RR 
IO’ 5 of 5 0 of 5 2 of 5 
105 5 of 5 0 of 5 5 of 5 
10% 5 of 5 5 of 5 5 of 5 
IO’ 5 of 5 3 of 5 5 of 5 
108 5 of 5 5 of 5 5 of 5 
Groups of five female, 5- to 6-week-old BALE/c mice were infected 
intranasally with the indicated doses of virus. Mortalities, including 
mice that had been sacrificed owing to severe infection and loss of 
>30% of body weight, that had occurred by day 14 after infection are 
shown. 
To analyze further the species specificity of the WR type 
I IFN receptor, the ability of supernatant from W&infected 
cells to inhibit type I IFN bioactivity from a number of differ- 
ent species was examined. Figure 66 shows that l318R 
inhibits type I IFN activity from all species tested, but in 
agreement with the binding data, human and rabbit IFN 
were inhibited most effectively, with supernatant from only 
lo3 cells causing complete inhibition of 5 U of IFN. Rat 
and bovine IFN were inhibited less efficiently, requiring 
supernatants from 104 cells to inhibit the activity of 5 U of 
IFN, and the supernatant from lo5 cells was required to 
cause complete inhibition of 5 U of mouse IFN. In all cases, 
supernatants from vAB18Rinfected cells tested at the 
same concentrations mediated no inhibition of the IFN 
activity (data not shown). 
Virulence of VV Lacking B18R in Mice 
The contribution of B18R to VV virulence was tested in a 
murine intranasal model (Turner, 1967; Williamson et al., 
1990) in which at doses of >/lo4 plaque-forming units (pfu) 
of VV WR, there is an extensive respiratory infection, fol- 
lowed by virus dissemination and death. To be certain 
that any difference observed in the phenotype of WR and 
vAB18R was due only to loss of B18R, a virus revertant, 
vB18R-R, was constructed by transient dominant selec- 
tion (Falkner and Moss, 1990; lsaacs et al., 1990) in which 
the B18R gene was reinserted into the endogenous locus 
of the vAB18R genome. The viruses vABl8R and 
vB18R-R did not contain the selective marker that might 
affect their phenotype. The correct structure of the B18R 
gene and flanking genes in vB18R-R was confirmed by 
Southern blot hybridization and polymerase chain reaction 
(PCR) as described in Experimental Procedures (data not 
shown), and the expression of an active B18R gene was 
confirmed by binding assays with human 1z51-IFNa2 (data 
not shown). 
Table 1 shows that deletion of gene B18R reduced VV 
virulence. At doses of lo4 and lo5 pfu, most mice infected 
with WR or vB18R-R were sacrificed, owing to a severe 
infection and the loss of 230% of body weight, while 
vABl8R-infected animals survived. The attenuation of the 
virus was most clearly illustrated at a dose of 100 pfu, 
where mice infected with vAB18R showed no sign of ill- 
A 104 pfu lo5 pfu 
Figure 7. Virulence of vAB18R in Mice 
(A) Groups of five mice were intranasally infected with lo4 or lo5 pfu 
of WR (open circles), vAE18R (closed circles), or vB18R-R (open trian- 
gles). Mice were individually weighed and monitored for signs of ill- 
ness, scored from zero to four, daily. The mean percentage weight 
loss of each group f SEM, compared with the weight immediately 
prior to infection, and the mean value of signs of illness f SEM in 
each group are shown. All mice in the groups infected with WR (IO’ 
and lo5 pfu) or vB18R-R (lo5 pfu) and two mice infected with 10’ pfu 
of vB18R-Rdied orweresacrificed. Noneof thevABlBR-infected mice 
were sacrificed. 
(6) Mice were intranasally infected with lo4 pfu of vaccinia virus WR 
(open circles), vAB18R (closed circles), or vBlBR-R (open triangles). 
On the indicated days after infection, four animals infected with each 
virus were sacrificed and the titer of infectious virus in the lungs and 
the brain determined by plaque titration in BS-C-l cell monolayers. 
Virus titers are expressed as plaque-forming units per gram of tissue. 
The minimum detection limit of the plaque assay is indicated with a 
broken line. 
ness (ruffled fur, arched backs, or reduced mobility) and 
lost only a maximum of 5% of body weight (Figure 7A). 
In contrast, animals infected with WR or vB18R-R showed 
severe signs of illness and weight loss, and many were 
either sacrificed or died. Similarly, infection with lo5 pfu 
was very severe with WR and vB18R-R (all animals died 
or were sacrificed), and although all vAB18R-infected 
animals showed signs of illness and weight loss, they 
recovered. 
The replication of VV in the lungs and brains of mice 
on days 5 and 7 after infection was also investigated (Fig- 
ure 78). Only three out of eight vAB18R-infected mice had 
detectable virus in the lungs. In contrast, all eight mice 
infected with WR and seven out of eight mice infected 
with vB18R-R yielded virus and yielded it at higher titers 
than did the vAB18R-infected animals. Dissemination of 
vAB18R within the infected animal was even more re- 
stricted, and on day 5, no virus was detected in the brain, 
whereas all mice infected with WR or vB18R-R yielded 
virus. The type I IFN receptor, therefore, contributes to 
VV virulence in this model. 
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Discussion 
This study demonstrates that most orthopoxviruses ex- 
press a soluble receptor for type I IFNs, which in VV strain 
WR is encoded by gene B18R. This gene was predicted 
to encode a secretory IgSF glycoprotein with similarity to 
another W IgSF protein, B15R, and to the IL-1 and IL-6 
receptors (McMahan et al., 1991; Smith and Chan, 1991). 
The B15R protein was later shown to be a 50-60 kDa 
soluble IL-10 receptor (Alcami and Smith, 1992; Spriggs 
et al., 1992), while B18R encodes a 60-65 kDa glycopro- 
tein that is expressed on the cell surface and is secreted 
from the cell (Ueda et al., 1990; Alcami and Smith, 1992; 
Morikawa and Ueda, 1993). Although B18R has 20% 
amino acid identity with B15R, it does not bind IL-1 or IL-6, 
and its ligand had hitherto not been identified (Alcami and 
Smith, 1992; Morikawa and Ueda, 1993). B18R was 
known, however, to encode the S antigen that is expressed 
by most orthopoxviruses, but not VV strain Lister (Ueda 
et al., 1969; Ueda et al., 1972; Amano et al., 1979; Ueda 
et al., 1990; Morikawa and Ueda, 1993). It is surprising 
that B18R is a type I IFN receptor, as it is an IgSF member, 
while other type I IFN receptors are CRF2 members (Cal- 
lard and Gearing, 1994). 
Characterization of the VV WR type I IFN receptor 
showed that the protein is expressed early during infection 
and has higher affinity for human IFNa and IFNP (Ko, 174 
PM) than do the human type I IFN receptors (200 pM to 
5 nM). This is consistent with the VV WR type I IFN receptor 
being an effective competitor for IFN binding in vivo. Cells 
infected with VV secreted 1 .l x lo4 type I IFN receptors 
per cell, lower than the number of IL-lp receptors (1 x lo5 
per cell) produced by the same virus (Alcami and Smith, 
1992). This difference may be partly attributable to expres- 
sion from an early (B18R) rather than a late (B15R) pro- 
moter, but may also reflect the retention of some B18R 
on the cell surface (Ueda et al., 1990; Alcami and Smith, 
1992; Morikawa and Ueda, 1993). Whether B18R present 
on the cell surface can still bind type I IFN is under investi- 
gation. 
The affinity of the baculovirus-derived B18R was 3-fold 
lower than that of the VV WR B18R, and, consistent with 
its higher affinity, VV WR B18R inhibited IFN binding to 
U937 cells more effectively than did baculovirus-derived 
B18R. This lower affinity may be due to the incomplete 
glycosylation of the B18R protein from insect cells. The 
sizes of the B18R protein derived from insect and mamma- 
lian cells (38 and 59 kDa, respectively) detected by ligand 
blotting under nonreducing conditions (Figure 4) were 
broadly consistent with the sizes observed from these cells 
(48 and 60-65 kDa, respectively) by immunoprecipitation 
and electrophoresis under reducing conditions (Alcami 
and Smith, 1992). The different running conditions may 
explain the different sizes observed. The size of the B18R 
type I IFN receptor was shown by ligand blotting to be 
highly conserved in orthopoxviruses (data not shown). 
The VV strain Wyeth type I IFN receptor has 78-fold 
lower affinity for human INFa than does the WR-derived 
protein, while the proteins were expressed at similar lev- 
els. The sequence of the B18R gene in VV Wyeth will, 
therefore, be of interest. The lack of expression of a type I 
IFN receptor by VV Lister was consistent with the previous 
observation that this virus does not express the S antigen 
(Amano et al., 1979), which was shown to be encoded by 
gene B18R (Ueda et al., 1990). It is also noteworthy that 
Wyeth, which expresses a low affinity receptor, and Lister, 
which expresses no receptor, were widely used smallpox 
vaccines that gave lower frequencies of postvaccinial neu- 
rological complications than many other strains (Fenner 
et al., 1988). Possibly the lack of a high affinity soluble 
receptor for human type I IFN contributed to the relative 
safety of these vaccine strains. 
With the exception of the binding of human type I IFN 
to bovine IFN receptors, the type I IFNs demonstrate a 
strict species specificity even to the degree that mouse 
and rat IFNs cross-react poorly. The broad species speci- 
ficity of the type I IFN receptor from W is therefore remark- 
able. This might be because the W receptor is an IgSF 
rather than a CRF2 member, and this may permit greater 
structural flexibility to confer the broad specificity. The VV 
type I IFN receptor has a very high affinity for human IFNa 
and IFNP (KD, 174 PM) and rabbit type I IFN, a high affinity 
for bovine (Ko, 1 nM) and rat type I IFN, and an affinity 
for mouse IFNP (KD, 27 nM) 150-fold lower than that for 
human IFNa. Nevertheless, this affinity is still sufficient 
for the receptor to bind and inhibit mouse IFNa, and, con- 
sonant with this, the virus lacking the B18R gene was 
attenuated in intranasally infected mice. 
The relative affinities of the VV type I IFN receptor for 
type I IFN from different species are relevant to the enig- 
matic origin of VV and which host(s) this virus might have 
naturally infected during evolution. Jenner introduced 
cowpox for vaccination against smallpox in 1798, but the 
smaHpox vaccines used this century are VV, not cowpox 
(Downie, 1939). Thus, sometime between 1798 and 1939, 
VV replaced cowpox as the smallpox vaccine. Molecular 
analyses of the genomes of cowpox, VV, and variola 
(Mackett and Archard, 1979; Goebel et al., 1990; Smith 
et al., 1991;Aguadoet al., 1992; Shchelkunovet al., 1993; 
Massung et al., 1994) have shown that VV is unlikely to 
have arisen by mutation from cowpox or variola or by re- 
combination between these viruses, and a favored hypoth- 
esis for the origin of VV is that it is an independent ortho- 
poxvirus that previously infected a species in which it is no 
longer endemic. Horsepox has been suggested (Baxby, 
1981), as early vaccinators were reported to obtain sup- 
plies of vaccine from poxvirus infections of horses when 
supplies from infected cows were scarce. The affinities of 
the VV type I IFN receptor for IFN from different species 
indicate that the mouse is less likely than human, rabbit, 
cow, or rat to have been a natural host. Consistent with 
this, an analysis of the species specificity of the W and 
cowpox IFNy receptor showed that these bound and inhib- 
ited the activity of lFNy from human, cow, and rat, but not 
mouse (Alcami and Smith, submitted). 
The importance of IFN for protection against virus infec- 
tion is illustrated by the consequences of direct IFN treat- 
ment and the inactivation of components of the IFN sys- 
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tern, but also by the numerous measures taken by viruses 
to counteract IFN (introduction). Many viruses, including 
VV, achieve resistance to IFN by targeting the intracellular 
IFN-induced enzyme PKR (for review, see Smith, 1994). 
But poxviruses also present an extracellular blockade of 
type II (Upton et al., 1992; Alcami and Smith, submitted) 
and type I (this paper) IFNs. The latter represents a novel 
mechanism for VV inhibition of type I IFN, the fourth VV 
protein that interferes with IFN and the fourth soluble cy- 
tokine receptor identified in poxviruses. 
Deletion of the poxvirus cytokine receptors has variable 
effects on virus virulence. Loss of the TNF receptor from 
myxoma virus attenuated the virus in rabbits (Upton et al., 
1991). Inactivation of the IL-lb receptor from VV caused 
a 100-fold increase in LDso when inoculated intracranially 
into mice (Spriggs et al., 1992). In contrast, intranasal in- 
fection, a more physiologically relevant route, with 
vABl5R caused an increase in virulence (Alcami and 
Smith, 1992). The effect of deletion of the IFNy receptor 
on virulence is unknown. Here, deletion of the IFNalP re- 
ceptor from VV WR is shown to attenuate VV in a murine 
intranasal model and to diminish virus replication in the 
lungsand dissemination to the brain. The degree of attenu- 
ation observed in this model is modest compared with 
that resulting from deletion of structural proteins of the 
envelope of extracellular enveloped virus (Engelstad and 
Smith, 1993; Parkinson and Smith, 1994). This may reflect 
the relatively low affinity of the VV type I IFN receptor for 
mouse type I IFN, and the retention by the Bl8R deletion 
mutant of other genes (E3L and K3L) that confer resistance 
to IFN. The VV type I IFN receptor shares 89% amino acid 
identity with an open reading frame (ORF) in variola major 
virus strains India-1967 and Bangladesh-1975 (Massung 
et al., 1993, 1994; Shchelkunov et al., 1993). Such a high 
degree of amino acid identity makes it probable that the 
variola protein would bind IFN with similar species speci- 
ficity and would have contributed to variola virus virulence 
in humans. 
Other soluble cytokine receptors expressed by poxvi- 
ruses (for TNF, IL-1 p, and IFNy) were recognized only after 
the sequencing of mammalian homologs, owing to their 
amino acid identity (24%-380/o) with the extracellular li- 
gand-binding domains of the cellular receptors. In con- 
trast, no mammalian homolog has been described for the 
VV type I IFN receptor. Preliminary analysis does not show 
any significant sequence similarity of Bl8R with the extra- 
cellular domain of the known human IFNalP receptors. 
However, the similar folding pattern of fibronectin type Ill 
and immunoglobulin domains (Barclay et al., 1993) may 
facilitate the interaction of two unrelated receptors with 
type I IFNs. If Bl8R has been acquired from the host, 
as seems likely for other poxvirus cytokine receptors, the 
sequence of the Bl8R gene may aid the cloning of a cellu- 
lar counterpart. Such a host protein might be a soluble 
inhibitor of IFN action or a cell surface agonist or antago- 
nist. Although an analysis of human serum IFN-binding 
proteins only identified a soluble-form of the 51 kDa IFN 
type I receptor (Novick et al., 1992, 1994), cross-linking 
of radiolabeled IFNa to cell surfaces identified multiple 
complexes (Colamonici et al., 1992). 
In summary, we have shown that the orthopoxviruses 
encode a high affinity IFNalP receptor of novel structure 
and broad species specificity. The presence of an IFNa/P 
receptor in the orthopoxvirus genome adds to the impres- 
sive array of anti-IFN mechanisms employed by the virus 
and emphasizes the importance of IFN in defense against 
viruses. Lastly, this study illustrates that the analysis of 
virus immune evasion mechanisms may reveal potentially 
novel components of the mammalian immune system as 
well as imparting fundamental information about virus 
pathogenesis. 
Experimental Procedures 
Cells and Viruses 
Human U937, HeLa, and D980R cells, mouse L929 cells, bovine 
MDBK cells, rat NRK cells, and rabbit RK13 cells were obtained from 
the Cell Bank of the Sir William Dunn School of Pathology (University 
of Oxford). Human TK-143B cells were obtained from the American 
Type Culture Collection. Cells were grown in minimal essential me- 
dium (MEM) (GIBCO) with 10% fetal bovine serum (FBS), except U937 
cells, for which RPM1 1840 (GIBCO) and 10% FBS were used. Sf 21 
insect cells and AcNPV were obtained from R. Posse (Natural Environ- 
ment Research Council Institute of Virology and Environmental Micro- 
biology, Oxford) and were cultured in TClOO medium (GIBCO) con- 
taining 10% FBS. The sources of W strains and other orthopoxviruses 
have been described (Alcami and Smith, 1992; Alcami and Smith, 
submitted). Coca1 virus was obtained from W. James (Sir William Dunn 
School of Pathology, University of Oxford). 
Cytoklnes 
Human recombinant IFNa2 (specific activity, 3 x 1 O8 Ulmg) was ob- 
tained from PeproTech (London, England) and was radioiodinated 
without loss of biological activity by using ‘*? Bolton-Hunter reagent 
(specific activity, 2000 Cilmmol; Amersham, England) to a specific 
activity of 40 pCi/ug (Langer and Peska, 1986). Human natural IFNa 
(specific activity, 1.5 x 108 Ulmg) derived from Namalwa cells was 
obtained from Wellcome (Beckenham, England), human recombinant 
lFN6 (specific activity, 2 x 108 Ulmg) from GIBCO BRL, mouse IFNa 
and lFN6 (specific activity, 4 x 10’ Ulmg and 1.3 x 1 Oe Ulmg, respec- 
tively) from Calbiochem, and recombinant human and mouse IFNy 
(1 x 10’ Ulmg) from Genzyme; bovine recombinant IFNal (specific 
activity, 1 x 10’ Ulmg) was a generous gift from R. A. Collins (Institute 
of Animal Health, Compton, England); and rat and rabbit type I inter- 
feron (specific activity, 1.9 x lo1 Ulmg and 3.9 x 10” U/mg, respec- 
tively) were from Lee Biomolecular Research Laboratories, Incorpo- 
rated (San Diego, California). 
Preparation of Supernatants from Virus-Infected Cells 
Cultures of TK-143B cells or Sf cells were infected with 10 pfulcell. 
Supernatants from orthopoxvirus- or baculovirus-infected cells were 
harvested 3 days postinfection and centrifuged at 3000 rpm for 10 
min at 4OC and the pellet discarded. Virus particles were removed by 
centrifugation at 16,500 rpm in a SW41 Ti rotor for 60 min at 4OC. 
The supernatants were then concentrated to that equivalent to 3 x 
10’ cells/ml in Centriprep-10 concentrators (10,000 MW cutoff; Ami- 
con) and stored at -2OOC. 
Biological Assays for IFN 
The biological activity of IFN from different species was assayed by 
its ability to inhibit coca1 virus plaque formation (Alcami and Smith, 
submitted). Human, mouse, bovine, rat, and rabbit IFN were assayed 
in cultures of human HeLa cells, mouse L929 cells, bovine MDBK cells, 
rat NRK cells, and rabbit RK13 cells, respectively. Cell monolayers in 
24-well-plates (Nunc) were pretreated in 0.5 ml of MEM containing 
10% FBS and the indicated doses of IFN and supernatants from ortho- 
poxvirus- or recombinant baculovirus-infected cultures. After an 16 
hr incubation at 37”C, the cells were infected with approximately 100 
pfu of coca1 virus and the cells incubated for a further 48 hr at 37OC in 
media containing 1.5% (w/v) carboxymethylcellulose. The percentage 
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inhibition of IFN activity was calculated by dividmg the number of 
viral plaques in the wells containing viral supernatant and IFN by the 
number of plaques in the wells receiving coca1 virus alone. Superna- 
tants from the infected cultures did not form plaques in the absence 
of coca1 virus. 
Cell Surface and Soluble IFN Receptor Bindlng Assays 
For cell surface receptor binding assays, cells were harvested and 
washed twice in ice-cold binding medium (RPM 1640 containing 1% 
[w!v] bovine serum albumin, 0.1% [w/v] NaN3, and 20 mM HEPES 
[pH 7.21). Cells (l@) were incubated in duplicate with i*51-IFNa2 in 
0.2 ml of binding buffer alone or containing lOO-fold excess of unla- 
beled IFN for 2 hr at 4°C with constant gentle agitation. The cells were 
subsequently washed twice in ice-cold protein-free binding buffer and 
resuspended in 0.1 ml of the same buffer. Bound and free ‘251-IFNu2 
were separated by phthalate oil centrifugation (Dower et al., 1985) and 
the tube tips excised and radioactivity counted in a gamma counter. 
Soluble receptor binding assays were performed in duplicate with 
supernatants from W-or baculovirus-infected cells by incubation with 
‘ZSI-IFNa2 in a final volume of 0.2 ml for 90 min at room temperature. 
The ligand receptor complexes were precipitated with polyethylene 
glycol (PEG) and the precipitate collected on Whatman GF/C filters 
as described (Symons et al., 1990). Nonspecific binding of ‘251-IFNa2 
precipitated with binding medium alone was subtracted. Binding data 
were analyzed with the LIGAND program (Munson and Rodbard, 
1980). 
Ligand Blotting 
Supernatants from lo5 VV- or lo4 baculovirus-infected cells were re- 
solved by SDS-PAGE under nonreducing conditions on a 7.5% gel 
and transferred onto 0.45 pM nitrocellulose (Schleicher and Schuell). 
After the filters were blocked in 3% (w/v) nonfat skimmed milk in 10 
mM Tris-HCI (pH 7.4) 140 mM NaCI, 0.02% (w/v) NaN, overnight at 
4°C the filters were probed with 10 nglml ‘251-IFNa2 in blocking buffer 
with or without 1 .O uglml cold IFN for 4 hr at room temperature. Blots 
were then washed three times for 30 min in blocking buffer, air-dried, 
and exposed to autoradiography film. 
Construction of Recombinant Vaccinia Viruses 
The W WR B16R deletion mutant, vAB16R (Alcamiand Smith, 1992) 
was used for the construction of a revertant virus containing the B16R 
gene in its endogenous locus by transient dominant selection (Falkner 
and Moss, 1990; lsaacs et al., 1990). A plasmid, pAA21, was con- 
structed in which a BamHI-Xbal DNA fragment, excised from pAA 
(Alcami and Smith, 1992) and containing the entire B16R gene and 
360 and 690 nt of the 5’ and 3’ flanking regions, respectively, was 
cloned into BamHI- and Xbal-cut pSJH7 (Hughes et al., 1991). This 
plasmid was transfected into cells infected with vAB16R, and after 
isolation of mycophenolic acid-resistant intermediate viruses, a re- 
vertant was isolated on D960R cells (Kerr and Smith, 1991) by using 
bthioguanine (Isaacs et al., 1990). The virus revertant isolated was 
termed vAA15 and is referred to here as vB16R-R. 
The genomes of vAB16R and vB16R-R were analyzed by using 
virus DNA extracted from virus cores (Esposito et al., 1961). Viral 
DNA was cut with three different enzymes and analyzed by Southern 
blotting using fluorescein-labeled probes specific for B16R and the 
right hand end of the genome. PCR analyses using oligonucleotides 
flanking the B16L, B17R, B16R, B19R, and B20R ORFs of W WR 
were also performed. These analyses confirmed that the genomic 
structure of each virus was as expected and that no other alterations 
had occurred at the right hand end of the virus genome (data not 
shown). 
Recombinant Baculovirus 
The recombinant baculoviruses expressing B15R (AcAA3). B18R 
(AcAA4), and B8R (AcAA5) are described elsewhere (Alcami and 
Smith, 1992; Alcami and Smith, submitted) and are referred to here 
as AcB15R AcB18R, and AcBBR, respectively. 
Assay of Virus Virulence 
Female BALB/c mice (5-6 weeks old) were anesthetized and infected 
intranasally with 20 ul of the diluted virus in 0.5% bovine serum albu- 
min in phosphate-buffered saline (Turner, 1967; Williamson et al., 
1990). Each day, mice were individually weighed and monitored for 
signs of illness, and those suffering a severe infection and having lost 
> 30% of body weight were sacrificed. To determine virus titers in 
organs, mice were sacrificed 5 or 7 days postinfection and their lungs 
and brains removed, weighed, dounce homogenized in 1 ml of phos- 
phate-buffered saline, frozen and thawed three times, and sonicated. 
Virus infectivity was determined by plaque assay on BS-C-l cells. 
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